Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EuBiologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"EuBiologics","sponsor":"POP Biotechnologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"EuBiologics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by EuBiologics

    Menu

    EuBiologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EuBiologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

              Details:

              The agreement aims to produce cholera vaccines including, Euvichol, an oral cholera vaccine for the prevention of cholera, a disease that is prevalent mainly in the developing countries.

              Lead Product(s): Euvichol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Euvichol

              Highest Development Status: Approved Product Type: Vaccine

              Recipient: GC Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EuBiologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

              Details:

              EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes, which is present top line interim results of a Phase 3 clinical trial.

              Lead Product(s): EuCorVac-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19

              Highest Development Status: Phase III Product Type: Vaccine

              Recipient: POP Biotechnologies

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EuBiologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea

              Details:

              Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested.

              Lead Product(s): EuCorVac-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Korea Institute of Science and Technology

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EuBiologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea

              Details:

              The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.

              Lead Product(s): EuCorVac-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY